It revealed highly variable placental transfer of potentially protective antibodies and emphasized the importance of pregnancy immunization timing to reach peak antibody levels prior to delivery.
This study revealed considerable variation in vaccine-elicited IgG placental transfer and a swift decline of both Env-specific antibodies (Abs) and functional Ab responses in the infants prior to the first challenge, illustrating the importance of pregnancy immunization timing to elicit optimal systemic Ab levels at birth.
Familial knowledge and practices regarding vaccination mostly depend on vaccination providers for guidance on immunization timing and administration.
Additional studies are needed including optimizing the inoculation dosage, route, immunization sequence, and timing of delivery for this prime-boost vaccination strategy.
It is also possible that the efficacy of annual influenza vaccination in anti-TNF treated patients could be improved by timing immunization with the decline in biological effect of the corresponding agent.
These include the ideal source and type of DC, the form of antigen and method of loading DC, whether to induce maturation, the route and timing of immunization, and the optimal clinical scenario.
There is little evidence to guide practice with respect to timing of immunization relative to HAART and dosing schedules in older children.
Little effort has been directed towards investigation of how these vaccines could be best used in asplenic person in order to determine optimum schedules, doses and timing of immunization, and we suggest that it is urgently needed.
In order to provide an effective vaccine against S. aureus, a number of unresolved issues in vaccine development relating to optimal antigenic target identification, criteria for acceptable efficacy, identification of target population, commercial development limitations, optimal timing of immunization strategy, storage, cold chain requirements and cost need to be addressed properly.
Additionally, there are issues relating to optimal antigenic target identification, criteria for acceptable efficacy, identification of the target population in children as well as adults, commercial development limitations, optimal timing of immunization strategy, storage and cold chain requirements, cost of development and cost effectiveness (64).
Among cases with documented timing of pentavalent immunization, 83%, 70%and69%9% received timely vaccination for pentavalent doses 1, 2 and 3, respectively.
